Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk Terry.

Slides:

Advertisements

Similar presentations

Treat Everyone to an LDL-C of 70mg/dl? Daniel Edmundowicz, MS, MD, FACC Associate Professor Of Medicine Director, Preventive Cardiology UPMC Cardiovascular.

Advertisements

Lipid Disorders and Management in Diabetes

Slide Source LipidsOnline CO O C CH 3 COOCH CH 3 Cl CH 3 OC COOC 2 H 5 CH 3 Cl CH 3 OCH 2 CH 3 COOH CH 3 C Fenofibrate Clofibrate.

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

CE-1 CRESTOR ® Clinical Development Efficacy James W. Blasetto, MD, MPH Senior Director, Clinical Research.

Role of Rosuvastatin in the Treatment of Dyslipidemia

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

Agents Used to Treat Hyperlipidemia. Hyperlipidemia 2 Atherosclerosis – accumulation of fatty substances on the inner wall of large and medium sized arteries.

Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.

Chapter 19 Agents Used to Treat Hyperlipidemia. Hyperlipidemia 2 Atherosclerosis – accumulation of fatty substances on the inner wall of large and medium.

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Primary Prevention With Statins: ACC/AHA Risk-Based.

Presentation Title R3 이지영 / 김 수 중교 수 님. Introduction Lowering LDL cholesterol levels with statins : Reduce the risk of cardiovascular disease Vascular.

Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Optimal low-density lipoprotein is 50 to 70 mg/dl:

Date of download: 6/26/2016 From: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta- analysis Ann Intern Med.

Double-blind, randomized trial in 4,162 patients with Acute Coronary Syndrome

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Proposal to Incorporate Trial Data Into a Hybrid.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Atherothrombosis J Am Coll Cardiol. 2012;60(10):

Date of download: 9/19/2016 From: Narrative Review: Lack of Evidence for Recommended Low-Density Lipoprotein Treatment Targets: A Solvable Problem Ann.

Search strategy and results Amir Kashani, et al. Circulation. 2006;114:

Christie M. Ballantyne, MD

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

The American College of Cardiology Presented by Dr. Steven E. Nissen

Figure 1 Boxes represent effect estimates and lines represent 95% confidence intervals. (A) Effect of evolocumab on the risk of major vascular events [cardiovascular.

Cholesterol Lowering and CV Risk: Meta-analyses

Copyright © 2001 American Medical Association. All rights reserved.

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

Triglycerides Cholesterol HDL-C or N NIDDM N or or N IDDM.

The Anglo Scandinavian Cardiac Outcomes Trial

AIM HIGH Niacin plus Statin to prevent vascular events

Copyright © 2012 American Medical Association. All rights reserved.

Lipoprotein(a), Cardiovascular Disease, and Contemporary Management

AIM-HIGH Niacin Plus Statin to Prevent Vascular Events

Oxford Niacin Trial.

What is the likely mechanism by which HDL-C reduces coronary heart disease?

FATS- Familial Atherosclerosis Treatment Study

Long-term Medical Management of the Liver Transplant Recipient: What the Primary Care Physician Needs to Know Siddharth Singh, MD, Kymberly D. Watt,

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Use of the Coronary Artery Calcium Score in Discussion of Initiation of Statin Therapy in Primary Prevention Erin D. Michos, MD, MHS, Michael J. Blaha,

A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.

Cardiovascular Disease Risk Reduction Advances in Dyslipidemia

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report Scott M. Grundy, Hidenori.

These slides highlight a cardiology grand rounds and cardiology research rounds presented by William James Howard, MD at St. Michael’s Hospital, in Toronto,

An assessment by the Statin Diabetes Safety Task Force: 2014 update

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report Terry A. Jacobson, MD, Matthew K. Ito,

Lipid Clinic Challenge

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

APOC3, Coronary Disease, and Complexities of Mendelian Randomization

Préparation ESC Septembre

Contemporary Evidence-Based Guidelines

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

LRC-CPPT and MRFIT Content Points:

LDL - How low can you go? Terry Jacobsen, MD

Major classes of drugs to reduce lipids

Rhanderson Cardoso, MD, Roger S

Volume 87, Issue 1, Pages (January 2015)

Delahoy PJ, et al. Clin Ther 2009;31:236-44

The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease Dean G. Karalis, MD Mayo Clinic Proceedings

Margaret B. Nolan, MD, David O. Warner, MD Mayo Clinic Proceedings

PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies.

James H O'Keefe, Jr et al. JACC 2004;43:

ATP III Guidelines Drug Therapy FUTURE RESEARCH.

Section 6: Update on lipid treatment guidelines

Presentation transcript:

Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk Terry A. Jacobson, MD Mayo Clinic Proceedings Volume 86, Issue 8, Pages 762-780 (August 2011) DOI: 10.4065/mcp.2011.0128 Copyright © 2011 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE The incidence of coronary heart disease (CHD) events as a function of apolipoprotein (Apo) B levels in randomized controlled trials involving regimens, including statins (red, purple), niacin (nicotinic acid; blue), fibrates (fibric-acid derivatives; green), or ezetimibe (orange). Separate regression lines are shown for trials of statins in primary and secondary prevention and niacin. Other lines represent individual trials for fibrates and ezetimibe. Individual studies for each treatment are detailed in the legend (filled symbol = treated group; empty symbol = control or placebo group). The event rate is predicted to approach 0 at an Apo B level of 54.6 mg/dL (statin, primary prevention population). Studies differ in methodology, CHD end point definitions, and comparator groups (eg, active treatment vs placebo, high dose vs low dose, combination therapy vs placebo). AFCAPS/TexCAPS = Air Force/Texas Coronary Atherosclerosis Prevention Study; CARDS = Collaborative Atorvastatin Diabetes Study; CLAS II = Cholesterol Lowering Atherosclerosis Study; FATS = Familial Atherosclerosis Treatment Study; FIELD = Fenofibrate Intervention and Event Lowering in Diabetes; HATS = HDL Atherosclerosis Treatment Study; HPS = Heart Protection Study; IDEAL = Incremental Decrease in End Points Through Aggressive Lipid Lowering; JUPITER = Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; LIPID = Long-Term Intervention With Pravastatin in Ischaemic Disease; PROVE-IT = Pravastatin or Atorvastatin Evaluation and Infection, high-dose atorvastatin group; 4S = Scandinavian Simvastatin Survival Study, simvastatin group; SEARCH = Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; SEAS = Simvastatin and Ezetimibe Aortic Stenosis, simvastatin-ezetimibe group; SHARP= Study of Heart and Renal Protection; SPARCL = Stroke Prevention by Aggressive Reduction in Cholesterol Levels; TNT = Treating to New Targets; VA-HIT = Veterans Affairs High-Density Lipoprotein Intervention Trial. Mayo Clinic Proceedings 2011 86, 762-780DOI: (10.4065/mcp.2011.0128) Copyright © 2011 Mayo Foundation for Medical Education and Research Terms and Conditions